BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Drupal: Date iCal//NONSGML kigkonsult.se iCalcreator 2.18//
METHOD:PUBLISH
X-WR-CALNAME;VALUE=TEXT:Calendar of Events
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:STANDARD
DTSTART:20261101T020000
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
RDATE:20271107T020000
TZNAME:EST
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20270314T020000
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:calendar.72363.field_date.0@calendar.lafayette.edu
DTSTAMP:20261105T152812Z
DESCRIPTION:Regulations\, information constraints\, and administrative burd
 ens are key  \ndrivers of provider behavior\; we use recent state-level po
 licies targeting  \ngabapentin as a natural experiment to study these mech
 anisms in prescribing  \ndecisions. Gabapentin\, an increasingly misused m
 edication with rapidly  \nexpanding off-label use\, has been subject to tw
 o distinct regulatory  \ninterventions: Drug-of-Concern (DOC) designation\
 , which expands PDMP  \nreporting without constraining prescribing\, and S
 chedule V classification\,  \nwhich imposes binding prescribing and docume
 ntation requirements. Using a  \nnovel dataset linking MarketScan claims (
 2016–2024) with CDC  \nmultiple-cause-of-death records\, and a stacked dif
 ference-in-differences  \nframework\, we document four main findings. Firs
 t\, DOC designation has no  \ndetectable effect on gabapentin prescribing.
  Second\, Schedule V  \nclassification leads to a sustained decline in pre
 scribing\, reducing  \ngabapentin prescribing by 18 to 25 percent (from a 
 pre-policy baseline of  \n12.2 patients per 1\,000) within eight quarters\
 , driven by reduced  \ncontinuation among established users. Third\, we fi
 nd little evidence of  \nharmful substitution: opioid prescribing does not
  increase\, co-prescribing  \nwith opioids declines\, and we find no evide
 nce of substitution toward  \npregabalin. Fourth\, Schedule V classificati
 on is associated with a meaningful  \nreduction in gabapentin-involved mor
 tality\, including opioid-co-involved  \noverdose deaths\, with no corresp
 onding change following DOC designation.  \nMechanism tests exploiting var
 iation in PDMP mandates and patient histories  \nshow that neither salienc
 e nor information effects generate measurable  \nchanges in prescribing\; 
 instead\, the behavioral response is concentrated in  \nsettings where Sch
 edule V classification raises administrative hassle costs.  \nCollectively
 \, the results demonstrate that only binding regulatory frictions  \nmeani
 ngfully reduce gabapentin use and associated harms\, while  \nmonitoring-o
 nly policies are largely ineffective.\n \n 
DTSTART;TZID=America/New_York:20261113T120000
DTEND;TZID=America/New_York:20261113T130000
LAST-MODIFIED:20261103T152627Z
LOCATION:Simon 311
SUMMARY:Economics Seminar - 'Regulatory Frictions\, Prescribing Behavior\, 
 and  \nUnintended Consequences: Evidence from Gabapentin Policies'
URL;TYPE=URI:https://calendar.lafayette.edu/node/72363
END:VEVENT
END:VCALENDAR